Key Takeaways
- AMD treatment depends on whether the condition is early, intermediate, wet, or late dry AMD.
- Wet AMD is commonly treated with anti-VEGF injections, while some patients may also receive photodynamic therapy.
- AREDS2 supplements may help slow progression in people with intermediate AMD or certain cases of late AMD.
- Regular eye examinations and retinal imaging are important for monitoring AMD and determining whether treatment is working.
Age-related macular degeneration (AMD) affects the macula, the central part of the retina responsible for detailed vision. It can make reading, recognizing faces, driving, and other activities requiring clear central vision more difficult. AMD does not usually cause complete blindness, but it can significantly affect central vision as the condition progresses.
Because AMD can develop differently from one person to another, treatment is not the same for everyone. The AMD disease treatment approach depends on the type and stage of AMD, whether abnormal blood vessels are present, how much vision has been affected, and findings from eye examinations and retinal imaging.
How Is AMD Treated?
AMD disease treatment depends primarily on the type and stage of the condition. Early AMD may not require medication or procedures, but regular eye examinations can help monitor changes. For intermediate AMD, an eye specialist may recommend AREDS2 nutritional supplements to help reduce the risk of progression to advanced disease in appropriate patients [1]. Wet AMD disease treatment may require injections that target abnormal blood vessel activity in the retina.
This means treatment is generally focused on slowing progression, controlling abnormal retinal changes, preserving useful vision, and helping patients maintain independence. In some situations, treatment can also improve vision, particularly when fluid associated with wet AMD is addressed promptly.
Understanding the Different AMD Types
There are two broad forms of AMD: dry and wet. Dry AMD is more common and can progress through early, intermediate, and late stages. Late dry AMD can involve geographic atrophy, where areas of retinal tissue become damaged.
Wet AMD, also called neovascular AMD, occurs when abnormal blood vessels develop beneath or near the retina. These vessels can leak blood or fluid, damaging the macula and causing more rapid changes in central vision.
Knowing which type is present is essential because the appropriate AMD disease treatment can differ considerably between dry and wet disease.
What Happens During Treatment?
For someone receiving AMD disease treatment, the process usually begins with a comprehensive eye examination. The ophthalmologist may examine the retina after dilating the pupils and use optical coherence tomography (OCT) to produce detailed images of retinal structures.
OCT can help identify fluid or other changes associated with wet AMD. Additional imaging may sometimes be performed when the doctor needs more information about the retinal blood vessels or the extent of disease [2].
The results help the ophthalmologist determine whether observation, supplements, injections, or another treatment approach is appropriate.
What Happens With Wet AMD?
Anti-VEGF injections are the most common treatment for wet AMD [3]. VEGF, or vascular endothelial growth factor, contributes to abnormal blood vessel growth and leakage. Anti-VEGF medicines work by blocking this activity, helping reduce leakage and slow further vision loss.
Before an injection, the eye is numbed and cleaned to reduce discomfort and infection risk. The medication is then delivered into the eye using a very small needle.
Although the procedure itself is usually brief, treatment for AMD disease often requires repeated appointments. Many patients initially receive injections about once a month, after which the schedule may be adjusted according to their response and the specialist’s assessment.
What About Dry AMD?
The approach to AMD disease treatment for dry AMD depends on its stage. There is currently no treatment that reverses early AMD, so patients may be monitored regularly to identify progression.
For people with intermediate AMD, AREDS2 supplements may help slow progression toward advanced AMD [4]. They are not recommended as a general treatment for AMD disease, and they do not prevent AMD from developing in people who do not have the condition.
AREDS2 contains specific amounts of vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. Because the formulation contains high doses of certain nutrients, patients should discuss whether it is appropriate with their eye-care professional.
AMD Treatment at a Glance
AMD Type or Stage | Common Management | Main Goal |
| Early dry AMD | Regular monitoring and healthy lifestyle measures | Monitor for progression |
| Intermediate AMD | Monitoring and AREDS2 when appropriate | Slow progression to advanced AMD |
| Wet AMD | Anti-VEGF injections | Reduce abnormal leakage and preserve vision |
| Late dry AMD | Monitoring, low-vision support, and appropriate rehabilitation | Maximize remaining vision and independence |
The right AMD disease treatment can therefore change as the condition progresses. A patient may initially require monitoring and later need more active management if new retinal changes develop.
How Do Doctors Know if Treatment Is Working?
Monitoring is an important part of AMD disease treatment. During follow-up visits, the ophthalmologist may compare visual acuity, symptoms, retinal photographs, and OCT scans with previous examinations.
For wet AMD, the presence or absence of fluid beneath or within the retina can help determine whether additional injections are needed [5]. Some people require ongoing treatment over an extended period, while treatment intervals may be lengthened when the condition becomes more stable.
Patients should also report new or worsening distortion, blurring, blind spots, or other changes in central vision promptly.
Can Treatment Restore Lost Vision?
The outcome varies depending on the type of AMD, how advanced it is, and how much retinal damage has already occurred. Wet AMD treatment can sometimes improve vision by reducing retinal fluid and controlling abnormal blood vessel activity, but treatment cannot always restore vision that has been permanently lost.
The primary aim of AMD disease treatment is often to preserve existing vision and prevent or slow further deterioration. Early assessment is particularly important when symptoms suggest that dry AMD may have progressed to wet AMD.
What Can Patients Do Alongside Treatment?
Medical treatment is only one part of managing AMD. Regular eye examinations allow changes to be identified and addressed appropriately. Patients may also be encouraged to avoid smoking, maintain a balanced diet, exercise regularly, and manage conditions such as high blood pressure.
For people experiencing significant vision loss, low-vision services and rehabilitation can provide practical strategies and devices that make everyday activities easier [6].
Self-monitoring can also be useful. Some patients may be advised to use an Amsler grid or another method recommended by their eye specialist to identify changes in central vision.
Why Follow-Up Appointments Matter
AMD disease treatment is often not a one-time process. The condition can change over time, and the treatment that is appropriate at one stage may not be necessary or sufficient at another.
Keeping scheduled appointments allows the ophthalmologist to monitor the retina, assess treatment response, identify new activity, and adjust the management plan when needed. Missing appointments can make it more difficult to detect changes promptly, particularly in wet AMD, where retinal fluid can recur.
Patients should also discuss any new medications, supplements, or changes in their health with their healthcare team.
Conclusion
AMD treatment varies according to the type and stage of the disease. Early AMD may primarily require monitoring, while intermediate AMD may benefit from AREDS2 supplements when appropriate. Wet AMD is commonly managed with anti-VEGF injections.
The overall goal of AMD disease treatment is to preserve vision, slow progression, and help patients maintain their quality of life. Regular eye examinations, appropriate retinal imaging, and timely attention to new visual symptoms are important parts of long-term care.
For anyone diagnosed with AMD, the most appropriate AMD disease treatment should be determined by an ophthalmologist based on the individual’s retinal findings, symptoms, stage of disease, and overall health.
References
- Boopathiraj, N., Wagner, I. V., Dorairaj, S. K., Miller, D. D., & Stewart, M. W. (2024). Recent updates on the diagnosis and management of age-related macular degeneration. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 8(4), 364–374. https://doi.org/10.1016/j.mayocpiqo.2024.05.003
- Castillo, M. M., Mowatt, G., Elders, A., Lois, N., Fraser, C., Hernández, R., Amoaku, W., Burr, J. M., Lotery, A., Ramsay, C. R., & Azuara-Blanco, A. (2015). Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: A systematic review. Ophthalmology, 122(2), 399–406. https://doi.org/10.1016/j.ophtha.2014.07.055
- Cheng, S., Zhang, S., Huang, M., Liu, Y., Zou, X., Chen, X., & Zhang, Z. (2024). Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: Progress from mechanisms to clinical applications. Frontiers in Medicine, 11, 1411278. https://doi.org/10.3389/fmed.2024.1411278
- Age-Related Eye Disease Study 2 Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA, 309(19), 2005–2015. https://doi.org/10.1001/jama.2013.4997
- Moraru, A. D., Danielescu, C., Iorga, R. E., Moraru, R. L., Zemba, M., & Branisteanu, D. C. (2024). Review of guideline recommendations for optimal anti-VEGF therapy in age-related macular degeneration. Life, 14(10), 1220. https://doi.org/10.3390/life14101220
- Hooper, P., Jutai, J. W., Strong, G., & Russell-Minda, E. (2008). Age-related macular degeneration and low-vision rehabilitation: A systematic review. Canadian Journal of Ophthalmology, 43(2), 180–187. https://doi.org/10.3129/i08-001
